Rafael Holdings, Inc. (RFL) stock intrinsic value fair value estimate & owner earnings analysis

Rafael Holdings is a clinical-stage drug developer. Its lead product candidate is Trappsol Cyclo, an intravenous treatment for Niemann-Pick disease type C1, a rare inherited disease. The company acquired the developer, Cyclo Therapeutics, on March 25, 2025. Rafael also holds smaller stakes in other early-stage health companies and a small amount of real estate. Revenue is tiny: $917 thousand in the year ended July 31, 2025 and $630 thousand in the first nine months of fiscal 2026. It comes from product sales and rent. What the business earns. On our measure (cash from operations, less working-capital swings, less stock compensation, less maintenance capital spending) the company has consumed cash every year. Per share, that measure was about -$1.30 in fiscal 2021, -$1.28 in 2022, -$0.56 in 2023, -$0.40 in 2024 and -$0.75 in 2025. Before fiscal 2021 the company was a different business, with real estate and other holdings, so we only use fiscal 2021 onward. The loss deepened in 2025 as Cyclo's trial spending was added: cash used in operations was $18.9 million in fiscal 2025 versus $7.8 million in fiscal 2024. Over the first nine months of fiscal 2026 it was $21.6 million. Because earnings are negative in every year, there is no earnings base to project forward, and none of the cases assumes the company will become profitable. What is credited, and what is not. The value we can name and support today is cash. Cash and equivalents were $30.5 million on April 30, 2026, down from $52.8 million on July 31, 2025, which is roughly $0.59 per share on about 52.0 million shares. We do not credit any value for FDA approval or commercial sales of Trappsol Cyclo. Approval has not happened, and we did not find final results of the pivotal Phase 3 trial in the sources we reviewed. The company reports it has finished the last patient visits of that trial and expects to file its New Drug Application in the second half of calendar 2026. An independent monitoring committee reviewed an interim look in June 2025 and recommended that the trial continue to its full 96 weeks. That is not evidence of efficacy. If the drug is approved and sells, the shares would be worth much more than we show here. We leave that out because it is a hoped-for event, not an established fact. Bear case ($0.00 per share). Spending continues at the recent pace of about $7.2 million a quarter after the trial, because launch preparation and other programs replace trial costs. The $30.5 million of cash would be exhausted in roughly four quarters. Revenue is far too small to cover the costs, so there is nothing left for shareholders unless new shares are sold at a much lower price. Equity value cannot fall below zero for a common shareholder, so we show $0.00. Base case ($0.31 per share). The company spends at the same pace for the next two quarters, about $14.4 million, while it completes the trial and prepares the New Drug Application. That leaves about $16.1 million, or about $0.31 per share. No value is credited for the drug beyond that cash. Bull case ($0.39 per share). Trial-related costs fall now that the last patient visits are done, and we assume cash burn averages $5 million a quarter over the same two quarters, about $10.0 million in total. The $5 million figure is our assumption, set below the recent pace. That leaves about $20.5 million, or about $0.39 per share. Approval and sales are not credited here either, because they are not yet secured. What would make this wrong. A positive Phase 3 result and FDA approval would be worth far more than the cash in these cases. A failed trial or an FDA refusal would leave the company with little beyond its remaining cash, which is what the bear case reflects. The annual report for the year ended July 31, 2025 said that cash on hand was expected to cover obligations for at least the next 12 months, but cash has fallen since then. The company's earlier investment in Cornerstone Pharmaceuticals shows the risk: Cornerstone received negative Phase 3 results for its lead drug in October 2021. Accounting judgements. Stock compensation is treated as a real cost. Working-capital changes are removed. The figures come from the company's annual reports. The latest quarterly report was read through public reporting and XBRL data, not the full filing text, so some detail on that quarter could not be checked directly. Working-capital figures for older years are less clean, because the company's reporting lines changed with the business. This is the first analysis of this company.